{"id":"824a7f7e-b230-52df-bc6b-5ca378fb9ad1","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-inhibits-cyp2e1","predicate":"decreases_in_recorded_comparison","statement":"RA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"a0dc2829-dc51-5d7b-a0c5-07dd1c87d32b","mechanism_event_label":"RA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.","subject":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"object":{"id":"cab0024c-2ee0-5cdd-bc3a-d3b372868085","slug":"cyp2e1","display_name":"Human cytochrome P450 2E1","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"a0dc2829-dc51-5d7b-a0c5-07dd1c87d32b","stable_key":"ca8e9e6a-6953-51ec-b712-2b06398a416d:ra-inhibits-cyp2e1-event","event_type":"experimental_observation","label":"RA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.","description":"### ra-inhibits-cyp2e1\n\nRA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.\nCompetitive inhibition reported for this enzyme. Clinical interaction at oral exposure was not tested.\nModel and exposure: Human recombinant enzyme / liver microsome study; in-vitro probe-substrate assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases. | 2019 | https://pubmed.ncbi.nlm.nih.gov/30466000/ | https://doi.org/10.1016/j.biopha.2018.11.040 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6072a4ae-d563-5466-a1b2-6d280255d346","slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"RA concentration series","sequence_order":0,"notes":""},{"entity":{"id":"cab0024c-2ee0-5cdd-bc3a-d3b372868085","slug":"cyp2e1","display_name":"Human cytochrome P450 2E1","entity_type_key":"protein"},"role":"measured outcome","stoichiometry":null,"state_label":"decrease","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"RA concentration series\", \"comparator\": \"Probe assay without RA\", \"endpoint\": \"RA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.\", \"effect_direction\": \"decrease\", \"combination\": \"single\", \"conditions\": []}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; recorded from source.","entity":null},{"dimension":"experimental_model","value_text":"Human recombinant enzyme / liver microsome study; in-vitro probe-substrate assay.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Rosmarinic acid collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"rosmarinic-acid","display_name":"Rosmarinic acid","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"RA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases. | https://pubmed.ncbi.nlm.nih.gov/30466000/ | https://doi.org/10.1016/j.biopha.2018.11.040","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference ra-inhibits-cyp2e1; Competitive inhibition reported for this enzyme. Clinical interaction at oral exposure was not tested.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"1976dcb6-a77f-5a35-a2d3-16056b389b4a","evidence_kind":"source_excerpt","locator":"Lines 193-199","start_line":193,"end_line":199,"excerpt":"### ra-inhibits-cyp2e1\n\nRA inhibited human CYP2E1 assay activity, IC50 61.0 micromolar.\nCompetitive inhibition reported for this enzyme. Clinical interaction at oral exposure was not tested.\nModel and exposure: Human recombinant enzyme / liver microsome study; in-vitro probe-substrate assay.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases. | 2019 | https://pubmed.ncbi.nlm.nih.gov/30466000/ | https://doi.org/10.1016/j.biopha.2018.11.040 | Access: Indexed primary abstract/metadata only; unextracted doses, figures and methods remain unknown.","model_system":"Human recombinant enzyme / liver microsome study; in-vitro probe-substrate assay.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"606cff22-a6ed-59cd-a84d-87f44c59dc25","stable_key":"import-ca8e9e6a-6953-51ec-b712-2b06398a416d","title":"Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"684b4eab1dc2c0057f679109770af0de9340af5cd933377b590298cf8a752956","revision_id":"4028d9c5-fb17-54c5-b72c-c6d21678a832","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}